SUSAN BLANEY to Osteosarcoma
This is a "connection" page, showing publications SUSAN BLANEY has written about Osteosarcoma.
Connection Strength
0.261
-
Outcome of Patients With Recurrent Osteosarcoma Enrolled in Seven Phase II Trials Through Children's Cancer Group, Pediatric Oncology Group, and Children's Oncology Group: Learning From the Past to Move Forward. J Clin Oncol. 2016 09 01; 34(25):3031-8.
Score: 0.109
-
Doxorubicin: role in the treatment of osteosarcoma. Cancer Treat Res. 1993; 62:55-73.
Score: 0.085
-
Phase II trial of topotecan administered as 72-hour continuous infusion in children with refractory solid tumors: a collaborative Pediatric Branch, National Cancer Institute, and Children's Cancer Group Study. Clin Cancer Res. 1998 Feb; 4(2):357-60.
Score: 0.030
-
Pediatric phase I and pharmacokinetic study of erlotinib followed by the combination of erlotinib and temozolomide: a Children's Oncology Group Phase I Consortium Study. J Clin Oncol. 2008 Oct 20; 26(30):4921-7.
Score: 0.016
-
A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: a Children's Oncology Group study. Pediatr Blood Cancer. 2008 Feb; 50(2):254-8.
Score: 0.015
-
Acute pancreatitis after ifosfamide therapy. Cancer. 1994 Sep 01; 74(5):1627-8.
Score: 0.006